CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. — CFSMEATLAS
CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Mensah, Fane F K, Armstrong, Christopher W, Reddy, Venkat et al. · Frontiers in immunology · 2018 · DOI
Quick Summary
This study looked at a specific type of immune cell marker called CD24 found on B cells (infection-fighting cells) in ME/CFS patients. Researchers found that ME/CFS patients have more CD24+ B cells than healthy people, and these cells behave differently when it comes to energy use and cell survival. The findings suggest that ME/CFS may involve problems with how B cells handle energy metabolism.
Why It Matters
Understanding the link between abnormal B cell markers and energy metabolism in ME/CFS could help explain the disease's hallmark fatigue and post-exertional malaise. This research identifies CD24 as a potential biomarker and suggests that B cell dysfunction may be connected to mitochondrial and metabolic abnormalities in ME/CFS.
Observed Findings
ME/CFS patients showed significantly elevated percentages of CD24+ viable B cells at baseline compared to healthy controls after 5-day culture (p<0.05).
CD24 expression showed a strong negative correlation with mitochondrial mass in B cells (R²=0.76; p<0.01).
CD24+ B cells demonstrated reduced viability and poor proliferative responses when stimulated through the B cell receptor, particularly with anti-IgM antibody stimulation.
Significant correlation was found between CD24 expression and glucose usage/lactate secretion, suggesting altered energy metabolism in CD24+ cells.
IgD+IgM+ memory B cells showed a strong positive association between CD24 expression and pAMPK (phosphorylated AMP-activated protein kinase).
Inferred Conclusions
CD24 expression on B cells may serve as a marker reflecting variations in energy metabolism across different B cell subsets.
Dysregulation of CD24-expressing B cells in ME/CFS represents a functional abnormality in B cell maturation and metabolic capacity.
Abnormal CD24 expression and mitochondrial dysfunction in B cells may contribute to immune system dysfunction in ME/CFS.
Remaining Questions
Does CD24+ B cell dysfunction in ME/CFS reflect primary mitochondrial disease or secondary metabolic stress from other causes?
What This Study Does Not Prove
This study does not prove that CD24+ B cell dysfunction causes ME/CFS or that correcting this abnormality will treat the disease. The in vitro findings may not fully reflect what happens in patients' bodies, and correlation between CD24 expression and metabolic markers does not establish causation. The study cannot determine whether these B cell changes are a cause, consequence, or independent feature of ME/CFS.
How do these in vitro findings translate to the in vivo immune environment of ME/CFS patients, and do CD24 changes correlate with clinical symptom severity?
Can interventions targeting CD24+ B cell metabolism or function improve outcomes in ME/CFS patients?
What upstream triggers or genetic/epigenetic factors drive the aberrant CD24 expression and altered B cell metabolism in ME/CFS?